Background: Physically inactive patients with chronic obstructive pulmonary disease (COPD) exhibit higher rates of exacerbations and symptoms of dyspnoea than active patients. Whether the use of COPD medication explains these differences is not known. Aim: This study evaluated differences in the use of COPD medication and the number of exacerbations due to physical activity. Methods: A COPD cohort (N ¼ 719) was followed through medical records to identify hospital admissions, and exercise activity was evaluated using mailed questionnaires. The national drug reimbursement registry identified drug purchases for one year. Results: The use of maintenance therapies, such as long-acting muscarinic antagonists (LAMAs), longacting beta agonists (LABAs), inhaled corticosteroids (ICS), and theophylline, did not differ significantly between physically active (N ¼ 346) and inactive (N ¼ 355) COPD patients. The cumulative dose of salbutamol (85 vs. 218 mg, adjusted P ¼ 0.01) and oral corticosteroids (OCS) (621 vs. 1068 mg, adjusted P ¼ 0.02) were significantly higher in inactive patients, regardless of disease severity. LABAs, LAMAs, and ICS were used in reduced doses in both patient groups compared to daily defined doses (DDD). Physical activity was independently associated with the number of hospital admissions and the use of OCS and short-acting bronchodilators. Conclusion: Physical inactivity in COPD was not associated with poorer use of maintenance therapies. In contrast, inactivity was independently associated with the number of exacerbations measured by hospital admissions and the use of OCS and short-acting symptom-relieving medications.
Introduction
Many retrospective observational and prospective intervention studies have demonstrated the importance of physical activity in chronic obstructive pulmonary disease (COPD) [1e6] . COPD patients are physically less active than age-matched fellow citizens. Objective measurements of physical activity revealed that the duration, intensity, and counts of movements are lower [7, 8] . Epidemiological studies and questionnaires revealed that patients physical activity is associated with exacerbation rate, survival, and the use of health care services [1e5] . However, less is known about the relationship of physical activity with COPD medication use.
The GOLD [9] recommendations and Finnish guidelines [10] were primarily based on symptom relief until 2011, and the 'add on' principle was followed during disease progression. Medication use started with short-acting bronchodilators when needed and continued with the regular use of long-acting bronchodilators. Inhaled corticosteroids were used if the patient experienced exacerbations or additional features of asthma, especially in severe disease. However, these guidelines are not always followed, and patient adherence to medication use also varies.
We followed a hospital-based COPD patient cohort since 2005. Exercise training activity was evaluated in this cohort in 2010 using a mailed questionnaire [11] . This study demonstrated that the sensation of dyspnoea was less disturbing and health-related quality of life (HRQoL) was better in active patients than inactive patients in all severity stages of COPD. Current smoking was also more prevalent in inactive patients, but co-morbidities, BMI, age and gender were not different between active and inactive patients. The present cross-sectional study gathered patient drug purchases from the National Drug Reimbursement Register during the same year (2010) [12] . We also evaluated hospital admissions due to exacerbations and pneumonia in the previous year 2009 because exacerbation history may have affected medication use and physical activity. Poor medication adherence is also associated with an increase in symptoms, hospitalizations, and mortality [13e17]. The present study compared the use of maintenance medications, which relieve persistent symptoms and prevent exacerbations, and 'when needed' rescue medication in spontaneously active and inactive COPD patients. The number of hospital admissions due to acute exacerbations of COPD (EACOPD) or pneumonia, courses of oral corticosteroids (OCS) and antibiotics were also evaluated.
Methods

Study subjects
Study subjects were identified from the Finnish Chronic Airway Disease Cohort [18] . This cohort was recruited from the pulmonary clinics of the Helsinki and Turku University Hospitals in Finland. A total of 959 patients with smoking-related COPD participate in a questionnaire study on HRQoL [19] , smoking status, and sensations of dyspnoea every other year. Patient drug purchases were obtained from the National Drug Reimbursement Registry. A total of 19 participants had withdrawn from the study and 30 patients died by the year 2010. Physical activity, dyspnoea and smoking status of patients in the present study were assessed in 2010 using a mailed questionnaire [11] . The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the study.
Assessment of clinical characteristics
All hospitals, health care centres and other outpatient clinics that treated COPD cohort patients were contacted to gather a complete, unbroken medical history of each participant. The medical history covered at least years 2009e2010. The patient's social security number was used to combine data from different sources. We identified the results of the latest flow-volume spirometry, weight, height and smoking status (>10 pack years) of the patients from medical records. GOLD stages are based on baseline spirometry results. The reference values for FEV 1 (forced expiratory volume in 1 s) used in clinical practice were validated in a large Finnish population sample of both genders and a wide range of age groups [20] . The COPD sub-phenotype 'frequent exacerbator' followed the definitions of the GOLD 2011 update: 2 oral corticosteroids treatments or hospital admissions in one year [9] .
Self-reported outcomes
The COPD study patients (n ¼ 827) received the questionnaire about their physical activity in 2010, and the response rate was 87% (n ¼ 719). Assessment of exercise activity was based on previously validated questions, which were modified to reveal the potential seasonal variation in outdoor activities. The questionnaire was previously validated in Finland in a large sample of healthy and chronically ill citizens [21] . Activity was assessed by the question: "How often do you exercise at least half an hour at the time with the intensity which makes you at least mildly short of breath and perspire?" The questionnaire consisted of multiple questions on the patient's performance status and exercise activities, which all correlated with the question quoted above. Patients were categorized as "physically active" when they reported exercising at least 2e3 times per week throughout the year, based on the recommendations of the American College of Sports Medicine and the American Heart Association [22] . The amount of dyspnoea was assessed using the modified Medical Research Council Dyspnoea Scale (mMRC) [23] . HRQoL was assessed using the AQ20 [19] questionnaire for the previous year (i.e., 2009).
COPD medications
The National Drug Reimbursement Registry is administered by the Social Insurance Institution of Finland, and this registry was used to trace all cohort patient drug purchases in 2010. A pharmacy provides a 3-month supply of prescribed medications, and medications are refilled every 3 months with a reimbursement. Anatomical Therapeutic Chemical classification was used to identify the medication, and the Nordic article number was used to recognize the medication format and package size. We assessed the use of inhaled medications, theophylline, oral corticosteroids, and antibiotics. Inhaled medications were classified in one of five categories: short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), short-acting beta agonists (SABAs), long-acting beta agonists (LABA) and inhaled corticosteroids (ICS). ICS and LAMAs may be used as a fixed combination or non-fixed therapy that is administered simultaneously by two devices. LABAs, LAMAs, ICS, and theophylline were considered regular maintenance therapies when at least half of the DDD was reached during the follow-up period. SABAs and SAMAs are rescue medications that are used when needed. Purchases of OCS and antibiotics were assesseded as markers for COPD exacerbations. The daily defined dose (DDD) according to the classification of the World Health Organization [25] was used to pool different pharmaceutical products into a single therapeutic category and enable comparisons of separate products. All patients were entitled to lower (45% of the costs) or higher (72% of the costs) reimbursement for COPD medications. The criteria for higher reimbursement are very severe airway obstruction (FEV 1 40% of predicted), frequent exacerbations and FEV 1 50% or a simultaneous diagnosis of asthma.
COPD exacerbations
The following independent markers of COPD exacerbations were used: 1) oral corticosteroid purchases, with exclusion of dexamethasone and hydrocortisone which are not commonly used for COPD exacerbations and 2) antibiotic purchases that are commonly used in the treatment of respiratory infections (e.g., penicillins, doxycyclines, macrolides, cephalosporines, and fluoroquinolones). Purchases of cephalosporines and penicillins, other than amoxicillin, did not correlate with OCS purchases, which suggests that these antibiotics were also frequently used for other purposes in the cohort. Therefore, these products were excluded. Each purchase of an oral corticosteroid product was considered an exacerbation, and we calculated the cumulative dose for comparison. Experts gathered all hospital admissions due to COPD exacerbations and radiologically verified pneumonias during 2009e2010 from the medical records. A patient was classified as a frequent exacerbator if he/she had at least 2 OCS purchases or hospital admissions due to an exacerbation during in 2010 [24, 26] .
Statistical methods
Statistical analyses were performed using the statistical software packages SPSS (version 17.0) and R Statistical Software (version 2.15). Comparisons of demographic and clinical characteristics in the subgroups were performed using either the Mann-Whitney or Chisquare tests, when appropriate. Generalized linear models adjusted for potential confounders were used to assess differences in several outcome markers between active and inactive patients.
Results
Clinical characteristics and medication use
Active COPD patients (N ¼ 346) exhibited significantly milder disease, better HRQoL, and less severe dyspnoea compared to inactive COPD patients (N ¼ 355) ( Table 1) . The numbers of current smokers and frequent exacerbators were higher in the inactive compared to active patients. Inactive patients more frequently used a LAMA þ LABA þ ICS combination and theophylline compared to active patients (Table 2) .
Medication dosing varied greatly. Patients whose purchases reached half of the DDD were considered regular users ( Table 3) . Half of the patients reached the DDD or greater for ICS. A similar trend was also observed for long-acting bronchodilators. We used a generalized linear model to adjust comparisons of the intersection between physical activity and FEV 1 because the inactive patients exhibited more advanced disease. None of the observed differences in the maintenance therapy remained significant after adjustment (p > 0.05).
The number of patients who did not purchase any COPD medication was higher in active patients, but this difference was not significant after adjustment to the FEV 1 . Most patients without medication had GOLD stages 1e2 disease, but there were also patients with GOLD 3e4 disease (N ¼ 13), patients who reported severe dyspnoea (N ¼ 19, mMRC scale 3e4), and patients who were treated with oral steroids (N ¼ 21).
Use of inhaled corticosteroids
ICS was regularly used by 55% (N ¼ 410) of the entire cohort. ICS was used more in GOLD stages 3e4 than stages 1e2 (76% vs. 45% of the patients, p 0.001), and asthma COPD overlap syndrome (ACOS, 78% vs. 48%, p 0.01) as recommended. ICS use was also greater in frequent exacerbators (78% vs. 22%, p 0.01) compared to the rest of the patients. The proportion of patients who used doses comparable to the DDD or more was higher in frequent exacerbators (57%) and ACOS patients (47%) than patients without either of these subphenotypes (22%). There were 246 ACOS patients in this cohort (N ¼ 246), and 14% of these patients did not use inhaled corticosteroids. Seventy-one percent of patients who had GOLD 3e4 disease and frequent exacerbations reached the DDD. Nineteen percent (N ¼ 86) of GOLD stages 1e2 patients without ACOS or a history of frequent exacerbations were using ICS. Single LABA (N ¼ 11) or LAMA-LABA combination (N ¼ 9) were extremely rarely used without ICS.
Rescue medication and exacerbations
A total of 347 (48%) of all patients had purchases of salbutamol, 64 (9%) patients purchased terbutaline, 168 (23%) patients purchased ipratropium, 75 (10%) patients purchased oral corticosteroids (most frequently methylprednisolone), and 136 (19%) patients purchased antibiotics during the follow-up year. Inactive patients used more short-acting bronchodilators, antibiotics, and oral corticosteroids than active patients ( Table 4 .) The differences in salbutamol and OCS purchases remained significant after adjustments for FEV 1 , age, gender and smoking, in contrast to regular medications. The cumulative doses of inhaled salbutamol, terbutaline, and ipratropium bromide that were used during the follow-up year were significantly higher in the inactive compared to active patients (picture 1.).
Exacerbation-related hospital admissions and pneumonias were also more frequent in inactive patients compared to active patients (Table 5) . Tables 4 and 5 report the results of patients with GOLD stages 1e3 disease because the self-reported exercise activity in the GOLD 4 disease was very low ( Table 1 ). The two activity groups became clinically very comparable to each other after the exclusion of the stage 4 disease. These analyses revealed that physically inactive patients had more severe exacerbations that were treated in the hospital than the active patients (mean number of events per patient during 2009e2010 was 0.90 vs. 0.31, p ¼ 0.001). Pneumonias were rare in both groups, and no significant differences were found between the activity groups (0.23 vs. 0.21). We studied the cumulative doses and the frequency of exacerbation events by including the GOLD 4 disease, and the differences showed similar trends, except for hospital admissions (i.e., the difference was no longer statistically significant). We analysed patients who did not use any maintenance therapy under the hypothesis that 'under treatment can lead to exacerbations' to examine causes other than exercise activity that may explain the differences found in the use of rescue and exacerbation medication. Patients without any medication (N ¼ 130) had fewer annual exacerbations as measured by OCS treatments (mean 0.21 vs. 0.92 per patient, P < 0.05) and hospital admissions (mean 0.03 vs. 0.21, P < 0.005), which was contrary to our expectation. We continued under the hypothesis that the 'lack of long acting bronchodilation can lead to increased use of short acting bronchodilators', but the opposite result was obtained. The mean cumulative dose of salbutamol was higher in patients who also used long- All of the comparisons between active and inactive patients remained statistically non-significant.
*DDD for budesonide 0.64 mg, fluticasone 0.5 mg, beclomethasone 0.8 mg, salmeterol 0.1 mg, formoterol 18 mg, tiotropium 18 mg, and for theophylline 0.4 mg. **At least one purchase in 2010.
Table 4
Comparison of the mean cumulative doses of inhaled rescue medication and OCS, and the number of treatments with antibiotics used commonly for respiratory infections between the physically active and inactive COPD patients during 2010. Thirty-seven (5%) patients used salbutamol more than the recommended maximal dose of 800 mg/day, and 92% of these patients were simultaneous LABA users.
Discussion
The present study demonstrated through the electronic health care records and drug claims that the inactive COPD patients suffered significantly more exacerbations as measured by hospital admissions and the use of OCS. To our knowledge, this study describes the use of medication in COPD based on physical activity for the first time. Inactive patients used slightly more maintenance medication as measured in doses and products than active patients, but no significant differences were found between the groups when the degree of airway obstruction was taken into account. However, the difference in use of shortacting bronchodilators remained statistically significant. This observation is consistent with our earlier finding that disregarding the disease stage in inactive patients who suffered more from the sensitization of dyspnoea than active patients [11] . Maximal bronchodilation improves COPD patients' physical performance, for example by decreasing dynamic hyperinflation [27, 28] . We found no evidence that physical activity would associate with the use of long-acting bronchodilators in this reallife COPD cohort. The results suggest that the patient may need parallel pulmonary rehabilitation or at least exercise guidance to fully achieve the benefits of the new therapies and achieve the best effectiveness of LAMAs and LABAs. Some recent studies reported the same observation [29, 30] . Our study design only observed an association, but no causal relationship, between physical inactivity and bronchodilators. Therefore, any conclusions should be cautious.
The drug imbursement data used in the present study illustrates the use of prescription medicines in COPD patients with high accuracy. Unfortunately, we could not compare doctors' prescriptions and purchases. Previously published epidemiological studies demonstrated that only 50% of COPD prescriptions are purchased after the first year [13e16]. Decreased adherence to medications is associated with the high cost of medication, increased age, current smoking, irregular clinic attendance, low expectation of the medication, the presence of comorbid illnesses, especially depression and anxiety [13e16]. The indication for prescriptions could not be traced in this study, which likely harmed our analysis of antibiotics as a marker of COPD exacerbation/respiratory infection. The same concern exists to a lesser extent for OCS purchases.
ICS was used more frequently and in higher doses in patients with severe disease, frequent exacerbations, and asthma COPD overlap, as recommended. The doses remained smaller than in randomized clinical trials in which the treatment guidelines are based [26, 31, 32] . This study was cross-sectional, and we cannot make strong conclusions about the effect of medications based on these results. However, hospital admissions in COPD have significantly reduced in Finland during the last 15 years [33] , which was interpreted to reflect the development of COPD medication. Our results suggest that it is possible to use smaller ICS/LAMA/LABA doses than clinical trials, and these doses are sufficient to prevent exacerbations, or that the results in the management of COPD could be further improved if the recommended doses were used.
Conclusion
This study investigated the relationship of COPD medication and physical activity, of which very little is known. Our study demonstrated that the use profiles of maintenance therapy in COPD did not differ between physically active and inactive patients in this hospital-based COPD cohort of all disease stages. The GOLD guidelines on medication were followed rather well in this present reallife cohort, but the doses that the study patients used remained smaller than in clinical trials. It is possible that the optimal effects of maintenance therapies, especially when targeted against exacerbations, are not reached because of the lower dosing than recommended. The results suggest that physical inactivity is not a surrogate marker of poor adherence to medication, unlike current smoking and frequent exacerbations. Physical activity was independently associated with a decreased number of exacerbations, which were treated in the hospital and at home, and the use of fewer short-acting rescue medications. These results further confirm the important role of physical activity in reducing COPD patients' symptoms, exacerbations and health care costs.
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